The Population Council has announced that dapivirine vaginal ring has now gained regulatory approval or authorization for use in 11 countries in East and southern Africa. Made of flexible silicone, the ring slowly releases the antiretroviral drug dapivirine in the women's private part over a one-month period. The ring was developed to provide a long-acting prevention method for women when higher-efficacy products like daily oral PrEP are not viable options. For more, VOA's Lindord Moudou spoke to Anita Garg, senior director for strategy and commercial relations at the Population Council.